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Resistance developed by microbes is challenging success stories of treatment of
infectious diseases with anti-microbials. Developing new antimicrobials against these
resistant organisms does not progress at the same speed. In an effort to address
this key issue, this work overviews the role of different stakeholders and discusses
preventative and control measures for effective management of available resources.
Roles and concerns of physicians, pharmacists and the public are also discussed.
More than anything, this situation requires immediate action to establish antimicrobial
stewardship program, control over the counter sale and promote public awareness. The
paper also confronts the idea of curbing the use of antimicrobials using mass media,
while detailing the consequences of non-therapeutic use. The role of policy makers
in taking global action is essential to establishing authority or agency for formulating
national guidelines and regulations for prudently using antimicrobials. To do this, this
paper recommend the establishment of a global fund. In conclusion, the race against
resistance is a collective responsibility requiring coordinated action at local, national,
regional and international levels to ensure sustained utilization of antimicrobials.
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INTRODUCTION
Antimicrobials are naturally occurring or synthetic chemical agents that kill or inhibit the growth of
microorganisms. They are one of the most successful forms of chemotherapy used in the treatment
of infectious diseases. Although evidence suggests the existence of antimicrobials back to 350–550
CE (Bassett et al., 1980; Nelson et al., 2010), their eﬀective use began in the mid-1940s making
revolutionary changes in treating infectious diseases. They remain the method of choice for such
treatment. However, their success stories are being challenged by resistance development due to
misuse/overuse of antimicrobials. Though observed even before the ﬁrst clinical use of penicillin
in the early 1940s (Wright, 2010); the current situation on resistance to almost all the antimicrobial
agents poses alarming risks to human and animal health worldwide.
Microbial resistance is a natural evolutionary processual response to selective pressure (Wright,
2010). As a result, antimicrobial agents fail to act against microbes (bacteria, fungus, parasites,
or viruses) resulting in persistent infection. Microbes acquire resistance by the incorporation of
resistance genes into the microbial genome or plasmids through conjugation, transformation,
or transduction (Tenover, 2006). It also occurs due to spontaneous mutations at the locus that
control drug susceptibility. Although it is a natural process, excessive and prolonged use facilitates
resistance and creates a serious threat.
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Antimicrobial consumption increased drastically between
2000 and 2010 (World Health Organization [WHO], 2014a).
In particular, BRICS countries (Brazil, Russia, India, China,
and South Africa) recorded the highest usage at around 76%
with an overall global increase of 36%. Between 2010 and
2030, antimicrobial consumption is expected to increase by 67%
worldwide. In particular, the amount of antimicrobials given to
farm animals will likely increase by two-thirds over the next
15 years without intervention (Van Boeckel et al., 2015). Studies
have found that countries with high consumption rates also have
high resistance rates (Ferech et al., 2006). To this end, developers
of new antimicrobials against these resistant microbes have failed
to progress at the same speed. In fact, only three new classes of
antimicrobials have been introduced since 2000 for human use
(Spellberg et al., 2008). Resistance is viewed as a global threat
and therefore, necessitating control to preserve the eﬃcacy of
antimicrobials by all possible means to continue to reap the
beneﬁts traditionally associated with them.
Given this background, this work provides an overview of
the role of diﬀerent stakeholders and discusses preventive and
control measures for eﬀective management to minimize the
development of resistance.
CONTROLLING THERAPEUTIC
OVERUSE
In general, antimicrobials are received for therapy or prophylaxis
during the course of infection, but at least one-half of patients
are receiving them unnecessarily or inappropriately (Hogerzeil,
1995). For instance, the most common cause of infections of the
upper respiratory tract is associated with viral agents (Zoorob
et al., 2012), where antimicrobials are ineﬀectual. Nevertheless,
general practitioners often prescribe antimicrobials for this
ailment (Bagger et al., 2015).
Studies from the Gulf Cooperation Council countries
(Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United
Arab Emirates) indicated that inappropriately prescribing and
overusing, including self-medication, appears to be the main
cause of resistance development (Memish et al., 2007; Aly and
Balkhy, 2012). However, from the physician’s perspective, it is
diﬃcult to diagnose in the early stages whether an infection is
viral or bacterial, especially in the cases of upper respiratory
tract infections and diarrhea (Kotwani et al., 2010). Behavioral
characteristics also play a crucial role in misuse and/or overuse.
For instance, patients sometimes demandmedication on the basis
that it was eﬀective in previous illnesses – physicians may comply.
The role of pharmacists in dispensing over the counter (OTC)
sale of antimicrobials is noteworthy. By law, it is prohibited in
many countries (Wirtz et al., 2013) but is nevertheless poorly
enforced and results in unlicensed distribution (Pan American
Health Organization [PAHO], 2004). While each stakeholder
plays a key role in restricting usage, according to a new survey
from the World Health Organization (WHO), pharmacists
are among the best positioned to promote appropriate use
of antimicrobials; they can play a crucial role in combating
resistance along with policy-makers and health practitioners
(World Health Organization [WHO], 2014b). Encouraging
pharmacists through awareness programs and incentives would
arrest the point of sale. Achieving compliance with OTC laws,
stricter enforcement and monitoring measures should all be
applied. There must also be severe penalties for non-compliant
pharmacies. An example of this is the retention of the operating
manager’s license or closure of the business in the most extreme
of circumstances.
The Infectious Disease Society of America and the Society
for Health Care Epidemiology of America published guidelines
for antimicrobial stewardship in 2007 to establish better
management of clinical treatment resources. These guidelines
aim to provide information on how to establish such programs
within health care institutions (Dellit et al., 2007). The primary
goal is to prevent or slow down resistance – these guidelines
are a logical ﬁrst step to facing the issue. Results from previous
studies suggest that the systematic stewardship program not only
helps to curb unnecessary usage, but also reduces the treatment
cost considerably. In one study, the program saved approximately
US$ 1 million in 18 months (Bantar et al., 2003). Similarly, Goﬀ
et al. (2012) showed that they achieved annual cost savings of
$832,590. Many countries have established national stewardship
programs and experienced beneﬁcial impacts even in resource-
limited settings.
Such a program is not the only way to combat mis- and
overuse of antimicrobials. Mass media campaigns in Belgium
resulted in a 36% decline in antimicrobial prescriptions and
prompted France to initiate a similar campaign directed
toward the public and general practitioners, particularly in
the implementation of rapid strep diagnostic tests for upper
respiratory infections (Sabuncu et al., 2009). In general, education
and awareness lead to better knowledge and also predicts
positive attitude (Awad and Aboud, 2015). Countries lacking
such initiatives need to implement media campaigns to educate
the public, while stewardship programs can help physicians in
hospitals to curb the unwanted use of antimicrobials. Countries
like India have many private practitioners as an important source
of medical care, especially in rural areas. Awareness programs
targeting these practitioners should therefore be considered since
they are generally the ﬁrst contact preference for medical care in a
local community (Rao, 2005). Thus, eﬀective programs targeting
the reduction of antimicrobials at all levels should be considered
failing which would result in a higher number of deaths
(World Health Organization [WHO], 2014a) in comparison to
mortalities caused by other major illnesses (Figure 1).
CONTROLLING NON-THERAPEUTIC USE
Initially, antimicrobials were administered to animals for
prophylactic and curative reasons. In the mid-1950s, small
quantities of antimicrobials such as penicillin and tetracycline
were found to enhance the feed-to-weight ratio and increase
growth rate in poultry, swine, and beef while reducing mortality
and morbidity (Stokestad and Jukes, 1950). As a result, the
Food and Drug Administration of the United States (US FDA)
approved these drugs in 1951 (Jones and Ricke, 2003). This
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FIGURE 1 | Antimicrobial death estimate in 2050 compared to
mortalities caused by other major illnesses. Source: Review on
Antimicrobial Resistance, 2014. Antimicrobial resistance: tackling a crisis for
the health and wealth of nations. Review on Antimicrobial Resistance,
London, UK.
resulted in the extensive use of anti-microbial drugs in farm
animal practice. The adverse eﬀect of the non-therapeutic use
of antimicrobials was not realized until Smith and Crabb (1957)
reported that diets containing tetracycline in pig and chicken
resulted in tetracycline resistant Escherichia coli. Studies quickly
proceeded to elucidate the impact of the non-therapeutic use of
antimicrobials in farm animals (Langlois et al., 1984; Aarestrup,
1999; Funk et al., 2006).
Although misuse and over-use in both human medicine and
intensive animal production have been recognized as one of
the important factors in the current crisis of resistance, non-
therapeutic use has led to multi-drug resistance on agents
never previously associated with farms (Levy, 2002). As a
result, the ﬁrst ban on farm use of antimicrobials as growth
promoters was enacted in 1986, in Sweden followed by Denmark,
United Kingdom, and other countries of the European Union
(Cogliani et al., 2011). However, many countries refuse to take
a ﬁrm position, despite the European experience that the ban
has reduced overall consumption in animals (Casewell et al.,
2003).
On the contrary, proponents argue that the withdrawal
of small quantities of antimicrobials resulted in heavy use
of antimicrobials to tackle the emergence of pathogens like
Salmonella sp. and Campylobacter sp. (Hao et al., 2014). This
has made some countries skeptical about the ban. Infectious
diseases’ pervasiveness is generally linked to poor hygiene
and management practices. For instance, strong sanitation
and hygiene procedures along with biosecurity measures helps
alleviate antimicrobials in addition to health checks and
vaccination programs. Likewise, frequent visits and checks by
animal health professionals ensures the well-being of animals and
is a key element in successful animal husbandry. However, in
reality antimicrobials are often used in farm animals with little
or no veterinary consultation. A survey in the USA reported
that only 42% of pig farms used the services of veterinary
medical practitioners. It is noteworthy to point out the role of
veterinary medical practitioner here. For instance, not all sick
animals are infected, nor do all infections require treatment with
antimicrobials (Weese et al., 2015). In this way, correct prognoses
and diagnoses are primary elements in decision making regarding
their usage. This rests ideally with veterinarians on the basis of
symptoms and appropriate laboratory investigation, including
culture and sensitivity tests as they pertain to individual animals
or groups. Such practices not only protect the animals against
diseases, but also provides economic beneﬁts. The animal
health practitioner is responsible for educating farmers and
ensuring that routine prophylactic use of antimicrobials should
never be a substitute for good animal health management.
For instance, good weaning practices and avoiding excessive
herd or ﬂock size reduces stress and improves animal’s natural
ability to ﬁght infectious diseases without assistance (Humphrey,
2006).
ROLE OF POLICY REGULATION IN
PRESERVING ANTIMICROBIALS
Policy-makers play a key role in tackling the fast-emerging
public health problem of resistance. The WHO has declared
antimicrobial resistance as a global concern, insisting national
surveillance systems. Harmonized integrated surveillance
of antimicrobial resistance has been implemented in a
limited number of countries, despite several international
recommendations during the last two decades (World Health
Organization [WHO], 2014a). Poor laboratory capacity,
infrastructure, and data management prevent eﬀective
surveillance, making it diﬃcult to discern patterns of resistance
and identify disease trends and outbreaks in many countries.
Each country should therefore establish an authority or agency
to formulate national guidelines and regulations in an eﬀort
to preserve the eﬃcacy of antimicrobials. Measures should be
consistent in these programs with the existing international
guidelines and codes of practice such as the Codex Guidelines
for Risk Analysis of Foodborne Antimicrobial Resistance
(CAC/GL 77-2011) (FAO/WHO, 2011), and the Codex Code
of Practice to minimize and Contain Antimicrobial Resistance
(CAC/RCP 61-2005) (FAO/WHO, 2005). Decision makers
must terminate non-therapeutic use of antimicrobials that are
also used in treatment of humans due to mounting evidence
that it contributes to antimicrobial resistance development and
endangers humanity.
Continuous surveillance and data integration of microbial
isolates are key components in assessing the current status of
resistance. The World Organization for Animal Health (OIE)
has developed standards toward this purpose that help to
detect the emergence and spread of resistant microbes that may
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cause foodborne disease (World Health Organization [WHO],
2014b). Establishing surveillance and monitoring programs
therefore addresses two key issues: early warning and drug
resistance. Developed nations may lend ﬁnancial/technical
support and help to develop a set of action plans to combat
rapidly developing antimicrobial resistance in coordination with
the WHO.
International ﬁnancial institutions need to organize to develop
a global fund toward creating an enabling environment for
underdeveloped and developing countries to implement eﬀective,
evidence-based programs. Since many countries lack basic
surveillance and laboratory capacity, technical, and monetary
support is crucial to creating a culture of awareness and battling
antimicrobial resistance.
CURRENT STATUS, ACHIEVEMENTS,
AND CHALLENGES
In an eﬀort to address this alarming issue, the US FDA has
established a list of “qualifying pathogens” with the potential to
pose a serious threat to public health. Generating Antimicrobial
Incentives Now (GAIN) has been signed as part of the Food and
Drug Administration Safety and Innovation Act to encourage
development of new antibacterial and antifungal drugs. These are
required to treat serious or life-threatening infections, whereas
the Act provides incentives like designating eligibility as fast-
track products, or an additional 5 years of exclusivity to be added
to certain exclusivity periods (Food and Drug Administration,
2014).
As of March 2015, 36 new antimicrobials with a potential
to treat serious bacterial infections are under various stages
of clinical trials. Nevertheless, only 60% of drugs entering
phase 3 get approvals, resulting in about 5 new drugs or so.
Recently, the US FDA approved three new antimicrobials:
dalbavancin, oritavancin, and tedizolid to treat patients with
bacterial infections (The PEW charitable Trusts, 2015). While
new drugs are being developed to meet the current crisis,
resources need to be allocated to meet the twin challenges of
preserving the existing antimicrobials and developing new
ones. Social media networking can contribute to preserving
existing antimicrobials. By targeting active users, it is
possible to communicate consequences of inaction more
frequently, eﬃciently, and on an unignorably mass scale.
As an example of a social media campaign, a recent report
from South Africa showed Twitter as a useful tool to improve
awareness of antimicrobial resistance (Goﬀ and van den Bergh,
2015).
The World Health Assembly recently endorsed a global
action plan with ﬁve major objectives, including: better
awareness and understanding of antimicrobial resistance,
strengthening surveillance and research, reducing the incidence
of infection, optimizing the use of antimicrobial medicines and
ensuring sustainable investment in countering antimicrobial
resistance (World Health Organization [WHO], 2015). It is the
responsibility of member states to initiate the plan and monitor
its success.
Several initiatives are also being made speciﬁcally to combat
non-therapeutic use, including the US FDA’s proposal to phase
out use over the course of three years. Companies have
indicated their compliance, despite it being only an unenforced
recommendation (Food and Drug Administration [FDA], 2015).
The companies have agreed to change the marketing status
of their products from OTC to Veterinary Feed Directive or
prescription.
A recent report from an OIE survey shows that 51% of
152 participating countries have completely banned growth
promoters, while 19% have committed to a partial ban (Rushton,
2015). Although legislation, surveillance systems, and bans on
non-therapeutic use are on the rise (Diaz, 2013), complete
elimination of this type of use is impossible without alternative
solutions.
Using antimicrobials for growth promotion generates more
proﬁt than their use for disease control. Hence, it has been a
common practice in livestock sector for the last half century.
However, in the case of good housing and hygiene, diﬀerences in
the growth rates were insigniﬁcant between consumers and non-
consumers of antimicrobials (Rushton, 2015). In some cases as in
the case of poultry, American farmers have actually experienced
economic loss when using antimicrobials (Graham et al., 2007).
It is therefore obvious that antimicrobials have little impact as
growth promoters and can in general be substituted with better
and more hygienic living conditions. In the case of farm animals,
whole herd health is the ultimate goal and to prevent infectious
disease, it is common to medicate the drinking water of the whole
herd, a commonly recognized means animals receive infectious
agents. Alternative treatments have proven eﬀective in treating
farm water quality. Ozone is an extremely reactive oxidant
and a very eﬀective sanitary agent in the food and agricultural
industries (de Candia et al., 2015; Pierron et al., 2015). This would
be an eﬀective substitute to antimicrobials. Although it is diﬃcult
to substitute antimicrobials in animal husbandry and, prudent
use is the only choice, possible measures to minimize their use
at all levels should be applied.
Research and development of new antimicrobials are
yet another vital area progressing at a slower rate because
of challenges encountered by pharmaceutical companies.
FIGURE 2 | Factors influencing race against antimicrobial resistance.
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Regulatory obstacles and economic disincentives force
companies to focus on more lucrative areas like cardiology and
oncology (Bettiol and Harbarth, 2015). International groups
have been aiming to create and test a new economic model
for antimicrobial research autarky. Sooner or later, such models
should accelerate research and development of new classes of
antimicrobials to control infectious agents. In an era of mounting
antimicrobial resistance, priority among researchers needs to
be targeted toward novel agents that circumvent, or at least,
minimize resistance. Figure 2 depicts the race against resistance
and how it is a complex issue facing a plenitude of factors; as a
result, every stakeholder must intervene by all possible means in
order to manage this crisis.
CONCLUDING REMARKS
Antimicrobial resistance is an alarming threat to global health
(Laxminarayan et al., 2013), where 10 million deaths are
estimated to occur annually by 2050 without appropriate
intervention. The WHO has drafted a sector-wide action plan
to be implemented globally to attempt this. Considering the
current situation, it is inevitable to establish legal frameworks and
monitoring programs on regional and national levels to ensure
appropriate usage of antimicrobials, which also means reducing
their use drastically. Governments and NGOs alike must develop
nationwide education and awareness programs, while regulatory
authorities should monitor the use of antimicrobials in hospitals
and health care centers. Incentive programs may be incorporated
to encourage appropriate usage, which will trigger stakeholders’
compliance.
Antimicrobial use as growth promoters need to be terminated.
Quality management programs in farms should be enforced
to prevent infection by improving sanitation, cleaning up
water supplies, etc. In addition, accelerating antimicrobial
development needs to be a priority. International collaboration
and capacities for prevention, surveillance, and control of
antimicrobials should be enhanced. In conclusion, racing against
antimicrobial resistance is a collective responsibility requiring
coordinated action at all levels to ensure sustained beneﬁts
of antimicrobials and head oﬀ any threats to humanity’s
future.
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